EMMA
Emmaus Life Sciences, Inc.
Price Chart
Latest Quote
$0.01
-0.00 (-2.91%)
Current Price
| Previous Close | $0.01 |
| Open | $0.01 |
| Day High | $0.01 |
| Day Low | $0.01 |
| Volume | 84,992 |
Stock Information
| Shares Outstanding | 70.19M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $674K |
| EPS (TTM) | $-0.13 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Book/sh | $-0.91 |
| Employees | 32 |
Financial Ratios
Returns & Margins
Ownership
| Insider Ownership | 47.08% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.14 |
| P/B | -0.01 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.01 |
| SMA50 | $0.01 |
| SMA200 | $0.01 |
| RSI | 46.18 |
| ATR | 0.0013 |
| Short Float | 0.09% |
| Short Ratio | 0.48 |
| Rel Volume | 1.34 |
Performance History
| Week | -12.73% |
| Month | -16.67% |
| Quarter | -33.79% |
| 6 Months | -12.73% |
| YTD | -26.15% |
| Year | -43.53% |
| 3 Years | -96.31% |
| 5 Years | -99.33% |
| 10 Years | -99.96% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.01 | 97,133 |
| 2026-06-17 | $0.01 | 206,627 |
| 2026-06-16 | $0.01 | 366 |
| 2026-06-15 | $0.01 | 1,650 |
| 2026-06-12 | $0.01 | 10,100 |
| 2026-06-11 | $0.01 | 0 |
| 2026-06-10 | $0.01 | 20,670 |
| 2026-06-09 | $0.01 | 0 |
| 2026-06-08 | $0.01 | 0 |
| 2026-06-05 | $0.01 | 164 |
| 2026-06-04 | $0.01 | 0 |
| 2026-06-03 | $0.01 | 366 |
| 2026-06-02 | $0.01 | 21,958 |
| 2026-06-01 | $0.01 | 713,771 |
| 2026-05-29 | $0.01 | 0 |
| 2026-05-28 | $0.01 | 0 |
| 2026-05-27 | $0.01 | 280,000 |
| 2026-05-26 | $0.01 | 95,200 |
| 2026-05-22 | $0.01 | 0 |
| 2026-05-21 | $0.01 | 185 |
| 2026-05-20 | $0.01 | 0 |
| 2026-05-19 | $0.01 | 0 |
About Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,201,000 | $1,342,000 | $2,588,000 | $3,312,000 |
| Cost Of Revenue | $1,201,000 | $1,342,000 | $2,588,000 | $3,312,000 |
| Total Revenue | $16,653,000 | $29,597,000 | $18,390,000 | $20,610,000 |
| Operating Revenue | $16,147,000 | $28,961,000 | $17,854,000 | $20,117,000 |
| Expenses | ||||
| Interest Expense | $5,492,000 | $7,383,000 | $5,013,000 | $3,101,000 |
| Total Expenses | $18,547,000 | $26,057,000 | $24,976,000 | $26,738,000 |
| Other Income Expense | $688,000 | $-630,000 | $354,000 | $-7,453,000 |
| Net Non Operating Interest Income Expense | $-5,218,000 | $-6,702,000 | $-4,333,000 | $-2,340,000 |
| Interest Expense Non Operating | $5,492,000 | $7,383,000 | $5,013,000 | $3,101,000 |
| Operating Expense | $17,346,000 | $24,715,000 | $22,388,000 | $23,426,000 |
| Selling And Marketing Expense | $6,002,000 | $8,635,000 | $7,493,000 | $5,878,000 |
| General And Administrative Expense | $10,687,000 | $14,891,000 | $13,170,000 | $13,438,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-6,453,000 | $-3,733,000 | $-10,625,000 | $-15,946,000 |
| Net Interest Income | $-5,218,000 | $-6,702,000 | $-4,333,000 | $-2,340,000 |
| Interest Income | $274,000 | $681,000 | $680,000 | $761,000 |
| Normalized Income | $-6,996,520 | $-4,799,150 | $-12,415,930 | $-12,500,400 |
| Net Income From Continuing And Discontinued Operation | $-6,453,000 | $-3,733,000 | $-10,625,000 | $-15,946,000 |
| Total Operating Income As Reported | $-1,894,000 | $3,540,000 | $-6,586,000 | $-6,128,000 |
| Net Income Common Stockholders | $-6,453,000 | $-3,733,000 | $-10,625,000 | $-15,946,000 |
| Net Income | $-6,453,000 | $-3,733,000 | $-10,625,000 | $-15,946,000 |
| Net Income Including Noncontrolling Interests | $-6,453,000 | $-3,733,000 | $-10,625,000 | $-15,946,000 |
| Net Income Continuous Operations | $-6,453,000 | $-3,733,000 | $-10,625,000 | $-15,946,000 |
| Pretax Income | $-6,424,000 | $-3,792,000 | $-10,565,000 | $-15,921,000 |
| Special Income Charges | $1,032,000 | $-821,000 | $-501,000 | $-365,000 |
| Earnings From Equity Interest | $0 | $-1,713,000 | $-1,913,000 | $-2,733,000 |
| Interest Income Non Operating | $274,000 | $681,000 | $680,000 | $761,000 |
| Operating Income | $-1,894,000 | $3,540,000 | $-6,586,000 | $-6,128,000 |
| Gross Profit | $15,452,000 | $28,255,000 | $15,802,000 | $17,298,000 |
| Per Share | ||||
| Diluted EPS | $-0.10 | $-0.07 | $-0.21 | $-0.32 |
| Basic EPS | $-0.10 | $-0.07 | $-0.21 | $-0.32 |
| Other | ||||
| Tax Effect Of Unusual Items | $144,480 | $16,850 | $476,070 | $-1,274,400 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,598,000 | $2,540,000 | $-7,766,000 | $-8,041,000 |
| Total Unusual Items | $688,000 | $1,083,000 | $2,267,000 | $-4,720,000 |
| Total Unusual Items Excluding Goodwill | $688,000 | $1,083,000 | $2,267,000 | $-4,720,000 |
| Reconciled Depreciation | $22,000 | $32,000 | $53,000 | $59,000 |
| EBITDA (Bullshit earnings) | $-910,000 | $3,623,000 | $-5,499,000 | $-12,761,000 |
| EBIT | $-932,000 | $3,591,000 | $-5,552,000 | $-12,820,000 |
| Diluted Average Shares | $63,234,789 | $53,105,388 | $49,439,867 | $49,253,156 |
| Basic Average Shares | $63,234,789 | $53,105,388 | $49,439,867 | $49,253,156 |
| Diluted NI Availto Com Stockholders | $-6,453,000 | $-3,733,000 | $-10,625,000 | $-15,946,000 |
| Tax Provision | $29,000 | $-59,000 | $60,000 | $25,000 |
| Other Special Charges | $-1,032,000 | $821,000 | $501,000 | $365,000 |
| Gain On Sale Of Security | $-344,000 | $1,904,000 | $2,768,000 | $-4,355,000 |
| Research And Development | $657,000 | $1,189,000 | $1,725,000 | $4,110,000 |
| Selling General And Administration | $16,689,000 | $23,526,000 | $20,663,000 | $19,316,000 |
| Other Gand A | $10,687,000 | $14,891,000 | $13,170,000 | $13,438,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-56,479,000 | $-47,756,000 | $-34,091,000 | $-21,450,000 |
| Total Assets | $23,602,000 | $35,179,000 | $48,225,000 | $56,734,000 |
| Total Non Current Assets | $16,835,000 | $23,670,000 | $41,936,000 | $47,643,000 |
| Other Non Current Assets | $222,000 | $296,000 | $263,000 | $295,000 |
| Non Current Note Receivables | $15,037,000 | $20,978,000 | $19,971,000 | $26,100,000 |
| Current Assets | $6,767,000 | $11,509,000 | $6,289,000 | $9,091,000 |
| Other Current Assets | $226,000 | $596,000 | $449,000 | $394,000 |
| Prepaid Assets | $894,000 | $1,131,000 | $1,065,000 | $986,000 |
| Inventory | $1,635,000 | $1,711,000 | $2,379,000 | $4,392,000 |
| Receivables | $2,623,000 | $5,524,000 | $375,000 | $1,040,000 |
| Accounts Receivable | $2,623,000 | $5,524,000 | $375,000 | $1,040,000 |
| Allowance For Doubtful Accounts Receivable | $0 | $-124,000,000 | $0 | - |
| Gross Accounts Receivable | $2,623,000 | $129,524,000 | $375,000 | - |
| Cash Cash Equivalents And Short Term Investments | $1,389,000 | $2,547,000 | $2,021,000 | $2,279,000 |
| Cash And Cash Equivalents | $1,389,000 | $2,547,000 | $2,021,000 | $2,279,000 |
| Debt | ||||
| Net Debt | $28,336,000 | $27,399,000 | $25,541,000 | $16,128,000 |
| Total Debt | $32,963,000 | $33,424,000 | $30,818,000 | $22,408,000 |
| Long Term Debt And Capital Lease Obligation | $3,061,000 | $4,065,000 | $6,279,000 | $7,911,000 |
| Long Term Debt | $2,246,000 | $2,226,000 | $3,726,000 | $4,650,000 |
| Current Debt And Capital Lease Obligation | $29,902,000 | $29,359,000 | $24,539,000 | $14,497,000 |
| Current Debt | $27,479,000 | $27,720,000 | $23,836,000 | $13,757,000 |
| Other Current Borrowings | $27,479,000 | $27,720,000 | $23,836,000 | $13,357,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $80,081,000 | $82,935,000 | $82,316,000 | $78,184,000 |
| Total Non Current Liabilities Net Minority Interest | $16,526,000 | $21,428,000 | $27,993,000 | $41,084,000 |
| Other Non Current Liabilities | $13,465,000 | $17,363,000 | $21,714,000 | $23,173,000 |
| Current Liabilities | $63,555,000 | $61,507,000 | $54,323,000 | $37,100,000 |
| Other Current Liabilities | $6,727,000 | $5,197,000 | $6,235,000 | $13,414,000 |
| Current Deferred Liabilities | $10,015,000 | $10,844,000 | $10,000,000 | $0 |
| Payables And Accrued Expenses | $16,911,000 | $16,107,000 | $13,549,000 | $9,189,000 |
| Interest Payable | $4,019,000 | $3,664,000 | $2,525,000 | $670,000 |
| Payables | $5,175,000 | $5,113,000 | $3,785,000 | $2,719,000 |
| Other Payable | $1,870,000 | $1,487,000 | - | - |
| Accounts Payable | $3,305,000 | $3,626,000 | $3,785,000 | $2,719,000 |
| Non Current Deferred Liabilities | - | - | $0 | $10,000,000 |
| Current Notes Payable | - | - | $2,367,000 | $800,000 |
| Equity | ||||
| Common Stock Equity | $-56,479,000 | $-47,756,000 | $-34,091,000 | $-21,450,000 |
| Total Equity Gross Minority Interest | $-56,479,000 | $-47,756,000 | $-34,091,000 | $-21,450,000 |
| Stockholders Equity | $-56,479,000 | $-47,756,000 | $-34,091,000 | $-21,450,000 |
| Other Equity Interest | $-16,869,000 | $-16,869,000 | - | - |
| Gains Losses Not Affecting Retained Earnings | $-2,995,000 | $-160,000 | $-2,619,000 | $-255,000 |
| Other Equity Adjustments | $-2,995,000 | $-160,000 | $-2,619,000 | $-255,000 |
| Retained Earnings | $-262,575,000 | $-256,122,000 | $-252,337,000 | $-241,266,000 |
| Long Term Equity Investment | - | $0 | $18,828,000 | $17,616,000 |
| Other | ||||
| Ordinary Shares Number | $63,865,571 | $61,845,963 | $49,583,501 | $49,311,864 |
| Share Issued | $63,865,571 | $61,845,963 | $49,583,501 | $49,311,864 |
| Tangible Book Value | $-56,479,000 | $-47,756,000 | $-34,091,000 | $-21,450,000 |
| Invested Capital | $-26,754,000 | $-17,810,000 | $-6,529,000 | $-3,043,000 |
| Working Capital | $-56,788,000 | $-49,998,000 | $-48,034,000 | $-28,009,000 |
| Capital Lease Obligations | $3,238,000 | $3,478,000 | $3,256,000 | $4,001,000 |
| Total Capitalization | $-54,233,000 | $-45,530,000 | $-30,365,000 | $-16,800,000 |
| Additional Paid In Capital | $225,896,000 | $225,333,000 | $220,815,000 | $220,022,000 |
| Capital Stock | $64,000 | $62,000 | $50,000 | $49,000 |
| Common Stock | $64,000 | $62,000 | $50,000 | $49,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $815,000 | $1,839,000 | $2,553,000 | $3,261,000 |
| Current Deferred Revenue | $10,015,000 | $10,844,000 | $10,000,000 | $0 |
| Current Capital Lease Obligation | $2,423,000 | $1,639,000 | $703,000 | $740,000 |
| Current Accrued Expenses | $11,736,000 | $10,994,000 | $9,764,000 | $6,470,000 |
| Net PPE | $1,576,000 | $2,396,000 | $2,874,000 | $3,632,000 |
| Accumulated Depreciation | $-356,000 | $-462,000 | $-430,000 | $-394,000 |
| Gross PPE | $1,932,000 | $2,858,000 | $3,304,000 | $4,026,000 |
| Leases | $15,000 | $39,000 | $39,000 | $39,000 |
| Other Properties | $1,887,000 | $2,720,000 | $3,166,000 | $3,827,000 |
| Machinery Furniture Equipment | $30,000 | $99,000 | $99,000 | $103,000 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-5,024,000 | $-4,967,000 | $-4,955,000 | $-3,390,000 |
| Finished Goods | $5,328,000 | $5,163,000 | $5,428,000 | $6,228,000 |
| Work In Process | $184,000 | $186,000 | $513,000 | $115,000 |
| Raw Materials | $1,147,000 | $1,329,000 | $1,393,000 | $1,439,000 |
| Treasury Shares Number | - | $0 | - | - |
| Investments And Advances | - | $0 | $18,828,000 | $17,616,000 |
| Non Current Deferred Revenue | - | - | $0 | $10,000,000 |
| Line Of Credit | - | - | $0 | $400,000 |
| Construction In Progress | - | - | $0 | $57,000 |
| Dueto Related Parties Current | - | - | - | $0 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-2,298,000 | $-1,520,000 | $-5,099,000 | $-1,327,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-2,286,000 | $-1,503,000 | $-5,073,000 | $-1,254,000 |
| Cash Flow From Continuing Operating Activities | $-2,286,000 | $-1,503,000 | $-5,073,000 | $-1,254,000 |
| Operating Gains Losses | $-45,000 | $1,073,000 | $-225,000 | $7,439,000 |
| Investing Activities | ||||
| Capital Expenditure | $-12,000 | $-17,000 | $-26,000 | $-73,000 |
| Investing Cash Flow | $2,500,000 | $-432,000 | $-2,387,000 | $-6,377,000 |
| Cash Flow From Continuing Investing Activities | $2,500,000 | $-432,000 | $-2,387,000 | $-6,377,000 |
| Net Other Investing Changes | - | $-2,647,000 | $-5,280,000 | $-6,304,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-1,353,000 | $2,477,000 | $7,233,000 | $7,411,000 |
| Cash Flow From Continuing Financing Activities | $-1,353,000 | $2,477,000 | $7,233,000 | $7,411,000 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Common Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-5,464,000 | $-7,500,000 | $-3,135,000 | $-8,779,000 |
| Issuance Of Debt | $4,111,000 | $9,977,000 | $10,368,000 | $16,190,000 |
| Interest Paid Supplemental Data | $2,246,000 | $2,453,000 | $1,335,000 | $945,000 |
| Income Tax Paid Supplemental Data | $48,000 | $83,000 | $4,000 | $21,000 |
| End Cash Position | $1,389,000 | $2,547,000 | $2,021,000 | $2,279,000 |
| Beginning Cash Position | $2,547,000 | $2,021,000 | $2,279,000 | $2,487,000 |
| Effect Of Exchange Rate Changes | $-19,000 | $-16,000 | $-31,000 | $12,000 |
| Changes In Cash | $-1,139,000 | $542,000 | $-227,000 | $-220,000 |
| Net Issuance Payments Of Debt | $-1,353,000 | $2,477,000 | $7,233,000 | $7,411,000 |
| Net Short Term Debt Issuance | $-853,000 | $660,000 | $4,309,000 | $-5,679,000 |
| Short Term Debt Payments | $-4,964,000 | $-7,390,000 | $-2,159,000 | $-7,379,000 |
| Short Term Debt Issuance | $4,111,000 | $8,050,000 | $6,468,000 | $1,700,000 |
| Net Long Term Debt Issuance | $-500,000 | $1,817,000 | $2,924,000 | $13,090,000 |
| Long Term Debt Payments | $-500,000 | $-110,000 | $-976,000 | $-1,400,000 |
| Long Term Debt Issuance | $0 | $1,927,000 | $3,900,000 | $14,490,000 |
| Net Investment Purchase And Sale | $2,508,000 | $2,232,000 | $2,919,000 | $0 |
| Sale Of Investment | $2,508,000 | $2,232,000 | $2,919,000 | $0 |
| Net PPE Purchase And Sale | $-8,000 | $-17,000 | $-26,000 | $-73,000 |
| Sale Of PPE | $4,000 | $0 | - | - |
| Purchase Of PPE | $-12,000 | $-17,000 | $-26,000 | $-73,000 |
| Change In Working Capital | $4,200,000 | $-2,617,000 | $2,209,000 | $2,110,000 |
| Change In Other Current Liabilities | $-1,480,000 | $-2,943,000 | $-3,094,000 | $-196,000 |
| Change In Other Current Assets | $868,000 | $239,000 | $591,000 | $566,000 |
| Change In Payables And Accrued Expense | $1,300,000 | $4,800,000 | $3,678,000 | $2,060,000 |
| Change In Prepaid Assets | $605,000 | $-214,000 | $-7,000 | $93,000 |
| Change In Inventory | $7,000 | $650,000 | $434,000 | $462,000 |
| Change In Receivables | $2,900,000 | $-5,149,000 | $607,000 | $-845,000 |
| Changes In Account Receivables | $2,900,000 | $-5,149,000 | $607,000 | $-845,000 |
| Other Non Cash Items | $-324,000 | $2,568,000 | $1,934,000 | $2,310,000 |
| Stock Based Compensation | $256,000 | $1,262,000 | $16,000 | $553,000 |
| Provisionand Write Offof Assets | $58,000 | $12,000 | $1,565,000 | $2,221,000 |
| Deferred Tax | $0 | $-100,000 | $0 | $0 |
| Deferred Income Tax | $0 | $-100,000 | $0 | $0 |
| Depreciation Amortization Depletion | $22,000 | $32,000 | $53,000 | $59,000 |
| Depreciation And Amortization | $22,000 | $32,000 | $53,000 | $59,000 |
| Earnings Losses From Equity Investments | $0 | $1,713,000 | $1,913,000 | $2,733,000 |
| Gain Loss On Investment Securities | $196,000 | $-3,373,000 | $-5,436,000 | $2,338,000 |
| Net Foreign Currency Exchange Gain Loss | $-245,000 | $1,911,000 | $2,773,000 | $2,004,000 |
| Gain Loss On Sale Of PPE | $4,000 | $1,000 | $24,000 | $-1,000 |
| Net Income From Continuing Operations | $-6,453,000 | $-3,733,000 | $-10,625,000 | $-15,946,000 |
| Change In Other Working Capital | - | - | $25,000 | $-30,000 |
| Purchase Of Investment | - | - | - | $0 |
Fetched: 2026-02-02